IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of XXXX .

@entity137 @entity19 @entity5 @entity3 @entity320
Interleukin-12 (IL-12) has been evaluated in both preclinical and clinical immunotherapy protocols as a potential therapy for @entity320 . However, delivery of IL-12 in the form of recombinant protein can result in severe @entity137 , and gene therapy has had limited success against B16.F10 @entity19 @entity320 . This study investigated the therapeutic effect of delivering a plasmid encoding IL-12 followed by electroporation on primary and secondary @entity5 . Three treatments of intratumoral (i.t.) plasmid injection and electroporation resulted in 80% of @entity19 with B16.F10 @entity320 being @entity5 free for >100 days (cure). The "cured animals" were resistant to challenge with B16 cells. In a separate experiment, B16 cells were injected on the opposite flank of the treated @entity5 on the day of treatment. Eighty-seven percent of control @entity19 developed a distant @entity5 while only 43.8% of @entity19 receiving two or three i.t. electroporation treatments developed a distant @entity5 . For examination of @entity5 development in the lungs, @entity19 were injected intravenously with @entity19 cells then treated with i.m. injections of plasmid with or without electroporation. Only 37.5% of @entity19 receiving i.m. injections and electroporation developed nodules in the lungs compared to 87.5% of @entity19 in the no-treatment group. The results show that administration of a plasmid encoding IL-12 with electroporation has a therapeutic effect on @entity5 as well as distant @entity5 and @entity3 .
